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ABSTRACT 
CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating 
proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS. The aim of our study was to determine the prevalence of genetic 
polymorphisms (codon 31 and 3’ untranslated region, 3’UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in 
patients with and without CNS tumors. 
DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital 
das Clínicas de Ribeirão Preto. 
METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Protein analysis was performed on 36 patients with CNS tumors, using 
the Western Blotting technique. 
RESULTS: The frequencies of the heterozygote (Ser/Arg) and polymorphic homozygote (Arg/Arg) genotypes of codon 31 in the control subjects were 
28.0% and 1.2%, respectively. However, the 3’UTR site presented frequencies of 24.2% (C/T) and 0.6% (T/T). These frequencies were not statistically 
different (P > 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3’UTR site). Regarding the protein 
expression in ependymomas, 66.67% did not express the protein CDKN1A. The results for medulloblastomas and astrocytomas were similar: neither of 
them expressed the protein (57.14% and 61.54%, respectively). 
CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were 
observed among Brazilian subjects. 
RESUMO
CONTEXTO E OBJETIVO: A investigação genética dos tumores do sistema nervoso central (SNC) provê valiosa informação sobre os genes que regulam 
a proliferação, diferenciação, angiogênese, migração e apoptose. O objetivo deste estudo é determinar a prevalência entre os polimorfismos genéticos 
(códon 31 e da região 3’ não traduzida, 3’UTR) e a expressão protéica do gene inibidor de quinase dependente de ciclina 1A (CDKN1A) em pacientes 
com e sem tumor do SNC.
TIPO DE ESTUDO E LOCAL: Estudo transversal analítico com grupo controle, desenvolvido no Laboratório de Biologia Molecular do Departamento de 
Oncologia Pediátrica do Hospital das Clínicas de Ribeirão Preto.
MÉTODOS: 41 pacientes com tumor do SNC e um grupo controle de 161 indivíduos sem câncer pareados por idade, sexo e etnia foram genotipados 
mediante uma reação de polimorfismo no comprimento de fragmentos de restrição (RFLP). A análise das proteínas foi realizada em 36 pacientes com 
tumor de SNC mediante Western Blotting.
RESULTADOS: A frequência do genótipo heterozigoto (Ser/Arg) e do homozigoto polimórfico (Arg/Arg) do códon 31 nos controles foi 28,0% e 1,2%, 
respectivamente. Entretanto, o sítio 3’UTR apresentou uma frequência de 24,2% (C/T) e 0,6% (T/T). Estas frequências não são significativamente 
diferentes (P > 0,05) daquelas observadas no grupo dos pacientes com tumor de SNC (19,4% e 0,0%, códon 31; 15,8% e 2,6%, sítio 3’UTR). 
Com respeito à expressão protéica, nos ependimomas, 66,67% não expressaram a proteína CDKN1A. Estes resultados foram similares entre os 
meduloblastomas e os astrocitomas, os quais não expressaram a proteína com 57,14% e 61,54%, respectivamente. 
CONCLUSÃO: Não foram encontradas diferenças significativas entre o padrão de expressão protéica, polimorfismos de CDKN1A e os três tipos de 
tumores de SNC em indivíduos brasileiros.
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InTROdUCTIOn
Central nervous system (CNS) tumors are the second most com-
mon type of pediatric cancer, exceeded only by leukemia, and they are 
the most common solid tumor during childhood. Every year, approxi-
mately 2,200 subjects younger than 20 years old are diagnosed with 
CNS tumors in the United States.1 The etiology of these tumors is mul-
tifactorial and probably varies according to the kind of tumor. 
Although the etiology of brain and CNS tumors is largely unknown, 
genetic investigation of CNS tumors provides valuable information 
about the genes regulating proliferation, differentiation, angiogenesis, 
migration and apoptosis in the CNS. Studying the gene expression of 
this type of neoplasm may identify genes that are candidates for direct-
ed gene therapy, in an attempt to increase the chances of cure for CNS 
tumor subgroups that have an unfavorable prognosis.2 One of these 
genes, cyclin-dependent kinase inhibitor 1A (CDKN1A), is a universal 
inhibitor of cyclin-dependent kinases (CDKs) and plays critical roles in 
G1/S and G2/M transition regulation. CDKN1A may lead to differen-
tiation of normal and transformed cells and suppression of malignant 
cell growth in vitro and in vivo.2 Moreover, it may lead to apoptosis in-
volving the tumor protein 53 (TP53) and retinoblastoma protein (RB) 
signaling pathways, in the same way as in senescence.3 Changes in the 
CDKN1A gene and its expression may have an important role in can-
cer pathogenesis, since its normal function comprises suspension of the 
cell cycle, terminal differentiation and apoptosis. Different types of neo-
plasms correlate with CDKN1A abnormalities, including cervical neo-
plasms, colorectal carcinoma, ovary carcinoma, bladder cancer, prostate 
cancer, hepatomas and others.4-8
Two polymorphisms have been identified and characterized in 
the CDKN1A gene. One of these, the codon 31 transversion (C→A), 
changes serine into arginine in the protein. The other one is located 20 
nucleotides downstream of the termination codon, in the 3’ untranslat-
ed region (3’UTR) of exon 3, with a transition of C→T.9,10 These two 
variants have recently been seen in a significant number of patients with 
lung, esophageal and breast cancer and sarcomas. 
Some studies have analyzed CDKN1A gene expression as a possi-
ble tool for diagnosis or as a prognosis indicator. Nadal et al.11 found 
that six out of seven laryngeal tumors of grade IV presented low lev-
els of CDKN1A, compared with 41 out of 42 tumors of grade I to III, 
which presented intermediate levels of CDKN1A. There is controver-
sy regarding the prognostic value of CDKN1A expression in breast tis-
sue. Two groups have associated increased expression with a good prog-
nosis in osteosarcoma,3,12 while other groups have correlated this with 
a worse prognosis.13,14 The relationships between CDKN1A expression 
levels and the prognostic factors in other types of tumor are similarly 
contradictory. 
Because of the high prevalence of CNS tumors in Brazil (18.3%), 
and continuing the previous work15 that detected the presence of CD-
KN1A gene polymorphisms through sequencing, the goal of this study 
was to determine the prevalence of CDKN1A gene polymorphisms in 
CNS tumor patients and control individuals. Furthermore, this study 
sought to analyze associations between these polymorphisms and the 
risk of developing the disease and its expression, along with the relation-
ship with tumor malignancy grade. As far as we know, this is the first 
study in Brazil on these polymorphisms among a general population 
and among CNS tumor patients.
OBjECTIvE
The aim of this study was to determine the prevalence of genetic 
polymorphisms (codon 31 and 3’UTR) and protein expression of the 
cyclin-dependent kinase inhibitor 1A (CDKN1A) gene, and to deter-
mine the risk of developing CNS-like medulloblastoma (16 cases), as-
trocytoma (15 cases) and ependymoma (10 cases).
MATERIAl And METhOdS
Patients and controls 
Tumor tissue stored in the Pediatrics Laboratory tumor bank was 
used. This tissue came from patients younger than 18 years of age who 
were treated for medulloblastoma (n = 16), ependymoma (n = 10) and 
astrocytoma (n = 15) in the Pediatric Oncology and Hematology De-
partment and the Neurosurgery Department of Hospital das Clínicas da 
Faculdade de Medicina de Ribeirão Preto (HC-FMRP-USP). The use of 
human tissue was approved by the institution’s Ethics Committee (pro-
cedural number 9375/2003). 
The criterion used for sample inclusion was the anatomopatho-
logical diagnosis, in addition to the availability of samples containing 
deoxyribonucleic acid (DNA) and proteins in amounts and of qual-
ity appropriate for the analysis. The classification of the tumors ana-
lyzed was based on the World Health Organization (WHO) nomen-
clature, 2000. 
Genomic DNA samples extracted from peripheral blood lympho-
cytes were used as controls. These came from the Pediatrics Laborato-
ry controls bank and their use was approved by the Ethics Committee 
of the participating institution (HC-FMRP-USP) (procedural number 
9374/2003). The control group was paired with the patients according 
to sex, age and ethnicity, and was formed by 97 female and 64 male sub-
jects, with ages ranging from five months to 20 years, without any his-
tory of neoplastic or genetic disease. Epidemiological data on the study 
population were obtained by means of a standard interviewer-adminis-
tered questionnaire that gathered data on social habits, health problems, 
family history of cancer and ancestry.
The human subject protocol was approved by the Ethics Commit-
tee of HC-FMRP-USP (procedural number 7709/2004), and written 
informed consent was obtained from all subjects or their parents.
Polymerase chain reaction
Genomic DNA was extracted using the modified protocol for Tri-
zol reagent-BD (Invitrogen, São Paulo, Brazil). The amplification of the 
polymerase chain reaction (PCR) was performed using a final volume 
of 25 µl. The PCR conditions were: 20 mM Tris-hydrochloride (Tris-
HCl) (pH 8.4); 50 mM potassium chloride (KCl); 1.5 mM of magne-
sium chloride (MgCl2); 0.1% weight/volume of gelatin; 0.2 mM of de-
oxyribonucleoside triphosphates (dNTPs); 100 ng of each primer; 1.0 
U of Taq DNA polymerase (Invitrogen); and 200 ng of genomic DNA. 
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The primers were designed for the 273 base pairs (bp) of exon 2 of 
the CDKN1A gene (codon 31), with 5’-GGATGTCCGTCAGAAC-
CCAT–3’ (upstream) and 5’- GGTGCCAGGCCGCCTGCCTC – 3’ 
(downstream). The cycling conditions were: 94 °C for 5 minutes, 34 cy-
cles of 94 °C for 40 seconds, 69 °C for 1 minute and 72 °C for 40 sec-
onds, followed by 10 minutes at 72 °C for the final extension. The prim-
ers designed for the amplification of the 300 bp of exon 3 of the CDK-
N1A gene (3’UTR) were 5’-GGGCGGCCAGGGTATGTAC–3’ (up-
stream) and 5’-CCCAGGGAAGGGTGTCCT G–3’ (downstream). 
The cycling conditions were 95 °C for 5 minutes, 30 cycles of 95 °C for 
30 seconds, 63 °C for 30 seconds and 72 °C for 30 seconds, followed by 
10 minutes at 72 °C for the final extension.
Analysis of restriction fragment length polymorphism
The 273 bp amplified fragment of exon 2 of the CDKN1A gene 
was produced and digested by the restriction enzyme BsmAI (New Eng-
land Biolabs, Beverey, Massachusetts, United States) using the modified 
protocol of Mousses et al.16 The digestion of the wild type allele (Ser/
Ser) presented a constant site for restriction enzyme recognition and 
yielded two bands: one of 142 bp and the other of 131 bp. The ho-
mozygote genotype for the polymorphic (Arg/Arg) allele was character-
ized by the presence of a second site for the BsmAI enzyme, yielding 
three bands: 131, 75 and 67 bp; and the heterozygote genotype (Ser/
Arg) showed four bands: 142, 131, 75 and 67 bp. After digestion, the 
reaction was analyzed by means of electrophoresis on 10% polyacrylam-
ide gel at 120V (Figure 1). The 300 bp fragment of exon 3 of the CDK-
N1A gene was produced and digested by the PstI enzyme (New England 
Biolabs) using the modified protocol of  Law et al.17 The polymorphism 
C→T gave rise to the loss of the PstI site. PstI digestion of the wild al-
lele, with the PstI site intact, presented two bands: one of 126 bp and 
the other of 174 bp. After digestion, the reaction was analyzed by means 
of electrophoresis on 2.0% agarose gel (Invitrogen, São Paulo, Brazil) at 
50V (Figure 2).
Western Blotting
The total protein fraction was obtained by Trizol reagent (Invitro-
gen, São Paulo, Brazil). The protein profile was analyzed by means of 
SDS-PAGE, using the discontinuous system proposed by Laemmli et 
al.18 Mini-gels of dimensions 8 x 7 x 0.01 cm, with acrylamide concen-
tration of 12% in the separation gel and 4% in the stacking gel, were 
used. The samples were prepared with 50 µg of protein for each 20 µl 
of sample buffer. The molecular weight marker used was Kaleidoscope 
Prestained (Bio-Rad, Hercules, California, United States). The proteins 
were transferred from the polyacrylamide gel into the nitrocellulose 
membranes through the Bio-Rad system, after their components had 
previously been immersed in the transfer solution. After running the 
gel, it was left for 15 minutes in transfer buffer and the transfer was per-
formed at 100V for one hour at 4-6 °C. The primary antibody used was 
anti-p21 mouse monoclonal (Santa Cruz, Biotechnology, Inc), diluted 
in 1% Tris-buffered saline Tween (TBST) at a concentration of 1:500, 
and the secondary antibody was anti-mouse IgG (Amersham Pharmacia 
Biotech, United States) bound to peroxidase, diluted in 1% TBST at a 
concentration of 1:2500. The intensity of the bands seen on the X-ray 
films was quantified using a computerized densitometer (GS 800 Cali-
brated Densitometer, Bio-Rad). The results were digitized and analyzed 
(Figure 3) using the reader software (Quantity One quantitation soft-
ware, Bio-Rad) and their intensity values were expressed in optical den-
sity units/square millimeter (OD/mm2) and recorded on a chart.
Figure 1. Polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) profile showing the polymorphisms in the 
cyclin-dependent kinase inhibitor 1A (CDKN1A) gene. Analysis of codon 
31 of the CDKN1A-BsmAI gene, in which M = molecular weight marker 
(100 bp); B = blank; lines 1 and 2 = homozygote for wild allele (Ser/Ser); 
line 3 = heterozygote (Ser/Arg); and line 4 = homozygote for polymorphic 
allele (Arg/Arg).
Figure 2. Polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) profile showing the polymorphisms in the 
cyclin-dependent kinase inhibitor 1A (CDKN1A) gene. Polymorphism 
detection at the 3’ untranslated region (3’UTR), PstI site, in which lines 
1 and 3 = homozygote for wild allele (C/C); line 2 = heterozygote (C/T); 
and line 4 = homozygote for polymorphic allele (T/T).
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors
Sao Paulo Med J. 2009; 127(5):288-94 291
Table 1. Frequency of cyclin-dependent kinase inhibitor 1A (CDKN1A) gene polymorphisms in central nervous system (CNS) tumors and controls
Polymorphisms Genotype
Number/total (%)
P OR (95% CI)
CNS tumors Controls
Codon 31 Ser/Ser 29/36 (80.6) 114/161 (70.8) 0.31 1.0 (reference)
Ser/Arg 7/36 (19.4) 45/161 (28.0) 0.61 (0.25-1.50)
Arg/Arg 0/36 (0.0) 2/161 (1.2) 1.00 0.78 (0.04-16.62)
3’UTR C/C 31/38 (81.6) 121/161 (75.2) 1.0 (reference)
C/T 6/38 (15.8) 39/161 (24.2) 0.39 0.60 (0.23-1.55)
T/T 1/38 (2.6) 1/161 (0.6) 0.37 3.9 (0.24-64.21)
Ser/Ser, C/C = homozygote for wild allele; Ser/Arg, C/T = heterozygote; Arg/Arg, T/T = homozygote for polymorphic allele; P = values were calculated using Fisher’s exact probability 
test; OR = odds ratio; CI = confidence interval.
Table 2. Frequencies of the cyclin-dependent kinase inhibitor 1A (CDKN1A) genotypes in the different types of central nervous system (CNS) tumor and 
controls
Tumor
Genotype
Codon 31 3’UTR
Ser/Ser Ser/Arg Arg/Arg C/C C/T T/T
Ependymomas 6/9 (66.7) 3/9 (33.3) 0/9 (0.0) 6/10 (60.0) 4/10 (40.0) 0/10 (0.0)
Controls 114/161 (70.8) 45/161 (28.0) 2/161 (1.2) 121/161 (75.2) 39/161 (24.2) 1/161 (0.6)
P 0.72 1.00 0.28 1.00
OR (95% CI) 1.0 (reference) 1.27 (0.30-5.29) 3.5 (0.15-81.26) 1.0 (reference) 2.07 (0.55-7.71) 6.23 (0.23-168.47)
Medulloblastomas 11/14 (78.6) 3/14 (21.4) 0/14 (0.0) 12/14 (85.7) 1/14 (7.15) 1/14 (7.15)
Controls 114/161 (70.8) 45/161 (28.0) 2/161 (1.2) 121/161 (75.2) 39/161 (24.2) 1/161 (0.6)
P 0.76 1.00 0.28 1.00
OR (95% CI) 1.0 (reference) 0.69 (0.18-2.59) 1.99 (0.09-44.08) 1.0 (reference) 2.07 (0.55-7.71) 6.23 (0.23-168.47)
Astrocytomas 12/13 (92.3) 1/13 (7.7) 0/13 (0.0) 13/14 (92.9) 1/14 (7.1) 0/14 (0.0)
Controls 114/161 (70.8) 45/161 (28.0) 2/161 (1.2) 121/161 (75.2) 39/161 (24.2) 1/161 (0.6)
P 0.19 1.00 0.28 1.00
OR (95% CI) 1.0 (reference) 0.21 (0.03-1.67) 1.83 (0.08-40.37) 1.0 (reference) 0.24 (0.03-1.88) 3.00 (0.12-77.40)
Ser/Ser, C/C = homozygote for wild allele; Ser/Arg, C/T = heterozygote; Arg/Arg, T/T = homozygote for polymorphic allele; P = values were calculated using Fisher’s exact probability test; OR = odds ratio; CI = confidence interval.
patient (2.6%) out of the 38 analyzed showed the C→T transition, and 
one patient in the control group also showed this (0.6%). There were no 
statistically significant differences between the patients and the controls 
(P = 0.37), with an odds ratio of 3.9 (CI = 0.24-64.21) (Table 1).
Analysis of the frequencies of codon 31 genotypes for each CNS tu-
mor type that was evaluated, in comparison with the controls, showed 
that there were no statistically significant differences between ependymo-
mas and controls (P = 1.00), medulloblastomas and controls (P = 1.00) 
or astrocytomas and controls (P = 1.00). The same was found regarding 
polymorphism at the 3’UTR site, and its frequencies were not statisti-
cally significant (Table 2).
Statistical analysis
Fisher’s exact probability test (Agresti)19 was used to analyze the fre-
quency of each genotype studied, in comparison with the total sample 
of patients and controls. It was also used for comparisons with the dif-
ferent types of tumor, with the aim of possibly correlating the genotypes 
found with the presence or absence of increased risk of development of 
CNS tumors. To analyze protein expression, the chi-square test, Fisher’s 
exact test and the nonparametric Kruskal-Wallis test were used. The sig-
nificance criterion used was a probability (P) level of less than or equal 
to 0.05. Odds ratios (OR) and 95% confidence intervals (CI)20 were cal-
culated as estimates of risk and degree of association. 
RESUlTS
Genetic analyses of CDKN1A in CnS tumors and controls
The frequencies of the C→A polymorphism in codon 31 and C→T 
polymorphism at the 3’UTR site of the CDKN1A gene in patients with 
CNS tumors and control subjects are shown in Table 1. Among the 36 
CNS tumor patients studied for the polymorphism in codon 31, none 
of them (0.0%) presented the transversion C→A in codon 31. How-
ever, out of the 161 controls studied, two subjects (1.2%) showed the 
transversion leading to the replacement of serine by arginine. The dif-
ferences in frequency seen between the patients and control group were 
not statistically significant (P = 1.00), with an odds ratio of 0.78 (CI = 
0.04-16.62) (Table 1). For the polymorphism at the 3’UTR site, one 
Figure 3. Results from Western Blot experiment showing the cyclin-
dependent kinase inhibitor 1A (CDKN1A) expression in central nervous 
system (CNS) tumors. Tu 145, Tu 467 and Tu 449 = no expression of 
CDKN1A protein; Tu 335, Tu 323, Tu 309, Tu 194, Tu 104 and Tu 100 = 
expressed CDKN1A protein.
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Analysis of CdKn1A protein expression in CnS tumors
To determine the clinical relevance of the polymorphisms in codon 
31 and at the 3’UTR site, we determined their correlation with CDK-
N1A protein expression in the CNS tumor samples (Table 3). Out of 
the 33 tumors evaluated, 39.39% expressed this protein and 60.61% 
did not (Figure 3). The differences between these two categories were 
not statistically significant (P = 0.22). The CNS tumors were analyzed 
in pairs (ependymomas-medulloblastomas, ependymomas-astrocytomas 
and medulloblastomas-astrocytomas) in order to evaluate their protein 
expression patterns. It was observed that in ependymomas, 66.67% did 
not express the CDKN1A protein, whereas the others did so. The re-
sults were similar for medulloblastomas and astrocytomas, with 42.86% 
and 38.46%, respectively. On the other hand, 57.14% and 61.54% did 
not express this protein. By means of Fisher’s test, it was seen that there 
was no significant difference (P = 1.00) in expression pattern percent-
age between the different types of tumor (Table 3). Correlation between 
the protein expression analyses and polymorphism showed  that the two 
genotypes (Ser/Ser and Ser/Arg) for polymorphism in codon 31 had sim-
ilar frequencies for the categories “not expressed” (64.0% and 50.0%) 
and “expressed” (36.0% and 50.0%). This finding was not statistically 
significant (P = 0.62), nor was the correlation for polymorphism at the 
3’UTR site (P = 0.99) (Table 4).
The polymorphism and protein expression analysis was compared 
to the degree of malignancy of each tumor. For this, pilocytic astrocy-
tomas (WHO grade I) and ependymomas (WHO grade II) were taken 
to be low-grade tumors, and anaplastic astrocytomas and ependymomas 
(WHO grade III) and medulloblastomas (WHO grade IV) were taken 
to be high-grade tumors. This comparison did not show any significant 
differences in codon 31 polymorphism (P = 0.99), 3’UTR site polymor-
phism (p=0.99) or protein pattern (P = 0.86), in relation to the degree 
of tumor malignancy (Table 5).
dISCUSSIOn
CDKN1A plays a central role in suspension of the cell cycle. How-
ever, it is possible that gene abnormalities could be responsible for the 
progression of a number of types of neoplasm.  
This was the first Brazilian study to analyze the most frequent CD-
KN1A gene polymorphisms (codon 31 and 3’UTR site) and protein ex-
pression relating to the second most frequent category of pediatric can-
cer (CNS tumors), in comparison with a control population.
Based on these data, we determined the prevalence of genetic poly-
morphisms of CDKN1A in a sample of 10 ependymomas, 16 medullo-
blastomas and 15 astrocytomas from the northwestern part of the State 
of São Paulo, compared with 161 control subjects. Our aim was to estab-
lish a correlation between these genetic polymorphisms and the risk of 
developing CNS tumors among children and adolescents. In this study, 
analyzing the total sample, no difference in the homozygote frequency 
for the codon 31 polymorphic allele (Arg/Arg) was found in CNS tu-
mors (0.0%), in comparison with the controls (1.2%). Regarding the 
normal homozygote (Ser/Ser) and heterozygote (Ser/Arg) genotypes, no 
significant difference was observed between the CNS tumors (80.6% 
and 19.4%, respectively) and the controls (70.8% and 28.0%, respec-
tively). Our allele frequency for the Arg variant (10.0%) was also similar 
to that observed by Koopmann et al.21 in brain tumors (8.5%).
The frequency of the Arg allele found in the control population of our 
study (0.15) was similar to that found by Chedid et al.22 in the United 
States (0.14). It has been suggested that the American and Brazilian pop-
ulations consist of miscegenation of whites and blacks, since these allele 
frequencies were found among the values observed by Birgander et al.23 
in African blacks (0.291) and in European Caucasians (0.039-0.0461). In 
Brazil, the African influence exerted through the slave population for three 
centuries, along with the Native Indian and colonizing European popula-
tions, could explain these results.24 Correlations between each polymor-
phism and one specific type of tumor did not show any significant dif-
ferences between ependymomas and controls (P = 0.73), medulloblasto-
mas and controls (P = 0.76) or astrocytomas and controls (P = 0.19), for 
codon 31. These data did not demonstrate any association between these 
polymorphisms and the risk of developing cancer. Moreover, similarly to 
our result, other studies also did not find any association between codon 
31 polymorphism and the risk of developing tumors.5,9 
The other polymorphism of interest was the 3’UTR site, which plays 
an important role in mRNA stabilization, cell proliferation and tumor 
differentiation and suppression.25,26 The prevalence of the homozygote 
genotype (C/C) was found to be 81.6% in the CNS tumors and 75.2% 
in the controls. The heterozygote genotype (C/T) was seen in 15.8% of 
the CNS tumors and in 24.2% of the controls. The homozygote geno-
type showed similar percentages for the polymorphic allele (T/T) in the 
CNS tumors (2.6%) and the controls (0.6%).
Table 3. Correlation between protein expression patterns among central 
nervous system tumors
Tumor
Categories
Not expressed Expressed
Ependymoma 4 (66.67%) 2 (33.33%)
Medulloblastoma 8 (57.14%) 6 (42.86%)
Astrocytoma 8 (61.54%) 5 (38.46%)
Table 4. Correlation between polymorphism frequencies and protein 
expression in central nervous system tumors 
Categories
Polymorphisms
Codon 31 3’UTR
Ser/Ser Ser/Arg C/C C/T
Not expressed 16/35 (64.0) 2/4 (50.0) 17/28 (60.7) 1/2 (50.0)
Expressed 9/35 (36.0) 2/4 (50.0) 11/28 (39.3) 1/2 (50.0)
P 0.62 0.99
Ser/Ser, C/C = homozygote for wild allele; Ser/Arg, C/T = heterozygote; Arg/Arg, T/T = homozygote for poly-
morphic allele; P = values were calculated using Fisher’s exact probability test.
Table 5. Correlation of the polymorphism and protein expression analysis 
with the clinical behavior of central nervous system tumors
Tumor Codon 31 3’UTR WB
Ser/Ser Ser/Arg C/C C/T Not expressed Expressed
LD 14/29
(48.3)
3/7
(42.9)
17/32
(53.1)
3/5
(60.0)
11/16
(68.8)
5/16
(31.3)
HD 15/29
(51.7)
4/7
(57.1)
15/32
(46.9)
2/5
(40.0)
9/17 (52.9) 8/17
(47.1)
P 0.99 0.99 0.86*
3’UTR = 3’ untranslated region; WB = Western Blotting; LD = low-grade tumor; HD = high-grade tumor; Ser/Ser, 
C/C = homozygote for wild allele; Ser/Arg, C/T = heterozygote; P = values were calculated using Fisher’s exact 
probability test, *calculated using the chi-square test.
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The frequencies of the polymorphic allele (T) were 0.11 in the CNS 
tumors and 0.13 in the controls. These were higher than the frequency 
(8%) observed by Shiohara et al.,27 and this difference may be related to 
the ethnic mix of the Brazilian population.24 
It was observed that all codon 31 and 3’UTR polymorphisms pre-
sented linkage disequilibrium. Thus, if a tumor was heterozygotic for 
codon 31, it was also heterozygotic for the 3’UTR site. Likewise, if it 
was homozygotic for the wild allele in codon 31, it was also homozy-
gotic for 3’UTR. Facher et al.10 found cosegregation of these two poly-
morphisms in a high percentage of cancer patients, thus suggesting that 
there was some functional difference in these allele variants that allowed 
subjects to be more susceptible to certain types of cancer. Polymorphism 
of the 3’UTR site may be located in a position that is required for rapid 
degradation of messenger CDKN1A and, for this reason, it would pre-
vent transient loss of activity. CDKN1A mRNA containing the codon 
31 variant could become more stable through association with 3’UTR 
polymorphism.
Konishi et al.26 also suggested that codon 31 polymorphism seemed 
to be only an innocent ligand and that the 3’UTR site that is tightly 
bound to codon 31 could be involved in the association between this 
polymorphism and the risk of tumors. Future experiments, taking this 
information into account, are required in order to evaluate the possi-
ble functional differences that contribute towards carcinogenesis, along 
with studies involving larger numbers of patients and controls.
CDKN1A expression in vivo, in human tumors, and its possible 
role in tumor progression and cell differentiation have been examined 
by investigators, with conflicting results.13 One of the purposes of the 
present study was to evaluate CDKN1A protein expression in CNS 
tumors, in order to correlate the expression levels with the develop-
ment and degree of malignancy of these tumors. Thirty-three CNS 
tumor samples were analyzed, 6 ependymomas, 13 astrocytomas, and 
14 medulloblastomas. We first compared CDKN1A protein expres-
sion among the three types of tumor, considering the intensity of the 
bands obtained through the Western Blotting technique. Analysis of 
the expression patterns using only two categories (“not expressed” and 
“expressed”) showed that the differences were not significant, thus in-
dicating that these tumors do not present a uniform pattern of CDK-
N1A expression. It is likely that this non-uniformity of expression pat-
tern occurs because of heterogeneity of the samples and, therefore, we 
analyzed these two categories in comparison with the different types of 
tumor. Even though the CDKN1A gene has a tumor suppressive func-
tion, it has been correlated with increased protein expression in some 
types of tumor, such as lung carcinoma, hepatocellular carcinoma and 
head and neck cancer.13,14 In relation to CNS tumors, Jung et al.28 
found that CDKN1A was frequently expressed in greater amounts in 
astrocytomas, anaplastic astrocytomas and glioblastomas. In addition 
to investigating the association between polymorphisms and protein 
expression, we analyzed our results through comparison of these poly-
morphisms and their expression with the degree of tumor malignancy. 
The statistical analysis showed that there was no significant difference 
between the relative clinical behavior of the polymorphisms (P = 0.99 
for codon 31 and 3’UTR) and the relative clinical behavior of the pro-
tein expression (P = 0.86). These results confirmed the previous analy-
sis, thus showing that there was no correlation between the presence 
of polymorphisms and the protein expression. 
One of the possible explanations for these results is the fact that 
CDKN1A alone is insufficient to stop the cell cycle and inhibit tu-
mor cell growth, considering that  mutations or loss of expression of 
other cell cycle/apoptosis genes such as PTEN, CDKN2A, MDM2, 
TP53 and RB is also associated with brain tumor etiology. More gen-
erally, these pathways are of importance in other cancer types, includ-
ing breast carcinoma, melanoma and colon carcinoma.29 Despite the 
potential importance of the cell cycle and apoptosis pathways in brain 
tumor etiology, very little has been published regarding the risk of 
brain tumors that is associated with the more common gene variants 
in these pathways, with the exception of the TP53 gene.29 On the oth-
er hand, investigation of protein expression levels alone indicates that 
this is not the active form. It is important to emphasize that the cell 
cycle regulation pathways are extremely complex and not completely 
clarified yet. 
COnClUSIOnS
No significant difference was observed between expression pat-
terns and polymorphisms of CDKN1A and three kinds of CNS tumors 
among Brazilian subjects. Therefore, the CDKN1A gene could have po-
tential application in gene therapy, because of its role in regulating cell 
cycle progression or in inducing interruption of the cycle cell. 
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